Raia Drogasil S.A Net Assets
Raia Drogasil S.A net assets. Based on the latest financial reports, Raia Drogasil S.A (RADL3) has net assets worth R$7.29 Billion BRL (≈ $1.43 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$25.13 Billion ≈ $4.93 Billion USD) and total liabilities (R$17.83 Billion ≈ $3.50 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Raia Drogasil S.A annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$7.29 Billion |
| % of Total Assets | 29.02% |
| Annual Growth Rate | 19.51% |
| 5-Year Change | 55.46% |
| 10-Year Change | 149.87% |
| Growth Volatility | 64.4 |
Net Assets of Raia Drogasil S.A (2000–2025)
Net assets of Raia Drogasil S.A from 2000 to 2025. This chart illustrates how Raia Drogasil S.A's net assets have evolved over time, based on quarterly financial data. See RADL3 net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Raia Drogasil S.A (2000–2025)
The table below shows the annual net assets of Raia Drogasil S.A from 2000 to 2025. For live market cap and overall valuation, see RADL3 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | R$7.34 Billion ≈ $1.44 Billion |
+13.87% |
| 2024-12-31 | R$6.44 Billion ≈ $1.26 Billion |
+6.87% |
| 2023-12-31 | R$6.03 Billion ≈ $1.18 Billion |
+11.57% |
| 2022-12-31 | R$5.40 Billion ≈ $1.06 Billion |
+14.50% |
| 2021-12-31 | R$4.72 Billion ≈ $925.91 Million |
+6.62% |
| 2020-12-31 | R$4.43 Billion ≈ $868.39 Million |
+8.57% |
| 2019-12-31 | R$4.08 Billion ≈ $799.87 Million |
+15.32% |
| 2018-12-31 | R$3.53 Billion ≈ $693.59 Million |
+8.75% |
| 2017-12-31 | R$3.25 Billion ≈ $637.78 Million |
+10.71% |
| 2016-12-31 | R$2.94 Billion ≈ $576.09 Million |
+10.51% |
| 2015-12-31 | R$2.66 Billion ≈ $521.31 Million |
+8.13% |
| 2014-12-31 | R$2.46 Billion ≈ $482.10 Million |
+5.58% |
| 2013-12-31 | R$2.33 Billion ≈ $456.60 Million |
+2.75% |
| 2012-12-31 | R$2.26 Billion ≈ $444.37 Million |
+2.88% |
| 2011-12-31 | R$2.20 Billion ≈ $431.91 Million |
+267.71% |
| 2010-12-31 | R$598.62 Million ≈ $117.46 Million |
+45.44% |
| 2009-12-31 | R$411.60 Million ≈ $80.76 Million |
+15.84% |
| 2008-12-31 | R$355.31 Million ≈ $69.72 Million |
-3.58% |
| 2007-12-31 | R$368.52 Million ≈ $72.31 Million |
+203.36% |
| 2006-12-31 | R$121.48 Million ≈ $23.84 Million |
+80.73% |
| 2005-12-31 | R$67.22 Million ≈ $13.19 Million |
-33.79% |
| 2004-12-31 | R$101.53 Million ≈ $19.92 Million |
+4.81% |
| 2003-12-31 | R$96.87 Million ≈ $19.01 Million |
+4.80% |
| 2002-12-31 | R$92.43 Million ≈ $18.14 Million |
+6.14% |
| 2001-12-31 | R$87.08 Million ≈ $17.09 Million |
+2.21% |
| 2000-12-31 | R$85.19 Million ≈ $16.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Raia Drogasil S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14111.2% over the analyzed period, indicating profitable operations and earnings retention.
Raia Drogasil S.A Net Assets Breakdown (December 2025)
Raia Drogasil S.A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$2.36 Billion | 32.22% |
| Common Stock | R$4.75 Billion | 64.87% |
| Other Comprehensive Income | R$173.82 Million | 2.37% |
| Other Components | R$39.40 Million | 0.54% |
| Total Equity | R$7.32 Billion | 100.00% |
Raia Drogasil S.A Competitors by Market Cap
The table below lists competitors of Raia Drogasil S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Perseus Mining Ltd
TO:PRU
|
$5.22 Billion |
|
New China Life Insurance Company Ltd
F:NCL
|
$5.22 Billion |
|
Portland General Electric Co
NYSE:POR
|
$5.22 Billion |
|
BRD Groupe Societe Generale SA
RO:BRD
|
$5.22 Billion |
|
Zhejiang Longsheng Group Co Ltd
SHG:600352
|
$5.21 Billion |
|
Linde India Limited
NSE:LINDEINDIA
|
$5.21 Billion |
|
Onex Corp
TO:ONEX
|
$5.21 Billion |
|
Shenzhen Everwin Precision Tech
SHE:300115
|
$5.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Raia Drogasil S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,428,768,000 to 7,322,129,000, a change of 893,361,000 (13.9%).
- Net income of 1,296,861,000 contributed positively to equity growth.
- Dividend payments of 652,764,000 reduced retained earnings.
- Other comprehensive income increased equity by 2,362,999.
- Other factors increased equity by 246,901,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$1.30 Billion | +17.71% |
| Dividends Paid | R$652.76 Million | -8.91% |
| Other Comprehensive Income | R$2.36 Million | +0.03% |
| Other Changes | R$246.90 Million | +3.37% |
| Total Change | R$- | 13.90% |
Book Value vs Market Value Analysis
This analysis compares Raia Drogasil S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 115.40x to 3.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | R$0.13 | R$15.22 | x |
| 2004-12-31 | R$0.14 | R$15.22 | x |
| 2005-12-31 | R$0.09 | R$15.22 | x |
| 2006-12-31 | R$0.17 | R$15.22 | x |
| 2007-12-31 | R$0.37 | R$15.22 | x |
| 2008-12-31 | R$0.39 | R$15.22 | x |
| 2009-12-31 | R$0.44 | R$15.22 | x |
| 2010-12-31 | R$0.64 | R$15.22 | x |
| 2011-12-31 | R$1.33 | R$15.22 | x |
| 2012-12-31 | R$1.32 | R$15.22 | x |
| 2013-12-31 | R$1.35 | R$15.22 | x |
| 2014-12-31 | R$1.43 | R$15.22 | x |
| 2015-12-31 | R$1.54 | R$15.22 | x |
| 2016-12-31 | R$1.70 | R$15.22 | x |
| 2017-12-31 | R$1.88 | R$15.22 | x |
| 2018-12-31 | R$2.04 | R$15.22 | x |
| 2019-12-31 | R$2.34 | R$15.22 | x |
| 2020-12-31 | R$2.54 | R$15.22 | x |
| 2021-12-31 | R$2.72 | R$15.22 | x |
| 2022-12-31 | R$3.11 | R$15.22 | x |
| 2023-12-31 | R$3.51 | R$15.22 | x |
| 2024-12-31 | R$3.88 | R$15.22 | x |
| 2025-12-31 | R$4.41 | R$15.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Raia Drogasil S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.71%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.93%
- • Asset Turnover: 1.74x
- • Equity Multiplier: 3.48x
- Recent ROE (17.71%) is above the historical average (12.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 2.27% | 0.74% | 1.94x | 1.58x | R$-6.59 Million |
| 2001 | 5.79% | 1.83% | 2.00x | 1.58x | R$-3.67 Million |
| 2002 | 8.68% | 2.65% | 1.97x | 1.66x | R$-1.22 Million |
| 2003 | 7.18% | 2.02% | 2.07x | 1.72x | R$-2.73 Million |
| 2004 | 7.83% | 1.86% | 2.19x | 1.92x | R$-2.20 Million |
| 2005 | 14.47% | 1.80% | 2.39x | 3.35x | R$3.00 Million |
| 2006 | 17.12% | 3.08% | 2.25x | 2.46x | R$8.65 Million |
| 2007 | 5.87% | 2.60% | 1.47x | 1.54x | R$-15.23 Million |
| 2008 | 14.40% | 4.06% | 2.11x | 1.68x | R$15.64 Million |
| 2009 | 18.12% | 4.34% | 2.35x | 1.78x | R$33.43 Million |
| 2010 | 14.87% | 4.44% | 2.17x | 1.54x | R$29.15 Million |
| 2011 | 3.12% | 2.52% | 0.86x | 1.44x | R$-151.42 Million |
| 2012 | 4.63% | 1.95% | 1.61x | 1.47x | R$-121.61 Million |
| 2013 | 4.34% | 1.62% | 1.72x | 1.55x | R$-131.71 Million |
| 2014 | 9.01% | 3.01% | 1.82x | 1.65x | R$-24.31 Million |
| 2015 | 12.92% | 3.82% | 1.89x | 1.78x | R$76.83 Million |
| 2016 | 15.39% | 3.98% | 1.99x | 1.94x | R$156.71 Million |
| 2017 | 15.86% | 3.87% | 2.04x | 2.01x | R$188.91 Million |
| 2018 | 14.36% | 3.39% | 2.01x | 2.10x | R$152.46 Million |
| 2019 | 19.19% | 4.40% | 1.43x | 3.04x | R$369.74 Million |
| 2020 | 11.10% | 2.41% | 1.45x | 3.17x | R$48.13 Million |
| 2021 | 16.07% | 3.12% | 1.63x | 3.16x | R$284.17 Million |
| 2022 | 18.65% | 3.43% | 1.69x | 3.22x | R$462.03 Million |
| 2023 | 17.71% | 3.11% | 1.69x | 3.37x | R$459.37 Million |
| 2024 | 18.63% | 3.08% | 1.76x | 3.44x | R$554.82 Million |
| 2025 | 17.71% | 2.93% | 1.74x | 3.48x | R$564.65 Million |
Industry Comparison
This section compares Raia Drogasil S.A's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $542,700,000
- Average return on equity (ROE) among peers: 22.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Raia Drogasil S.A (RADL3) | R$7.29 Billion | 2.27% | 2.45x | $5.22 Billion |
| d1000 Varejo Farma Participações S.A (DMVF3) | $838.14 Million | 0.24% | 0.75x | $45.67 Million |
| Empreendimentos Pague Menos S.A (PGMN3) | $247.26 Million | 44.12% | 3.07x | $350.44 Million |
About Raia Drogasil S.A
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.